Jacob Bell

Frederick, Washington, D.C.

Dad says I'm not an effective communicator. Senior Reporter @biopharmadive. Formerly @TheStreet, @educationweek, @mcclatchydc.

Articles

AstraZeneca quietly exits neuroscience

2 weeks ago | biopharmadive.com | Jacob Bell

AstraZeneca on Tuesday confirmed it has closed down its neuroscience research group to direct resources toward more “high value” projects.
AstraZeneca quietly exits neuroscience

2 weeks ago | finance.yahoo.com | Jacob Bell

Jacob Bell Thu, May 1, 2025, 7:54 AM 2 min read In This Article: This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. AstraZeneca on Tuesday confirmed it has closed down its neuroscience research group to direct resources toward more “high value” projects.
Biohaven stock slides on withdrawal of European marketing application

2 weeks ago | biopharmadive.com | Jacob Bell

Biohaven lost close to $400 million in market value Friday on news that the Connecticut-based drug developer had withdrawn an application to get one of its most advanced experimental therapies approved in Europe. The company first asked the European Medicines Agency for approval in late 2023, believing enough evidence had been gathered to show its drug, tentatively branded as Dazluma, is effective at treating “spinocerebellar ataxia,” a type of rare genetic disorder that impairs nerve cells.
Bristol Myers says schizophrenia drug launch ‘off to a solid start’

3 weeks ago | biopharmadive.com | Jacob Bell

A new, closely watched schizophrenia medication from Bristol Myers Squibb sold well in its first full quarter on the market, according to both the company and analysts. In its latest earnings report, Bristol Myers recorded $27 million in net sales from Cobenfy during the three-month period between January and March.
Bristol Myers’ prized schizophrenia drug stumbles in testing

3 weeks ago | biopharmadive.com | Jacob Bell

A brain drug at the center of a recent $14 billion acquisition has failed a large clinical trial, leading some Wall Street analysts to substantially lower their sales forecasts. Bristol Myers Squibb closed a deal to acquire the drug, Cobenfy, and its developer in March of last year, about six months before it was approved in the U.S. as a schizophrenia therapy.
Former Neumora CEO to lead Galapagos spinout

3 weeks ago | biopharmadive.com | Jacob Bell

Galapagos, a Belgium-based drugmaker, has selected the former head of a once-buzzy neuroscience startup to lead a spinout company that will lean on deals to build its slate of research programs. On Monday, Galapagos’ board of directors appointed Henry Gosebruch as CEO of the yet-to-be-officially-named spinout. The new company, which is part of a larger restructuring effort announced early last year, will come equipped with 2.45 billion euros — or roughly $2.5 billion — of Galapagos’ cash.
New research kindles excitement around stem cell therapies for Parkinson’s

4 weeks ago | biopharmadive.com | Jacob Bell

The most effective drug for Parkinson’s disease hasn’t changed in 50 years. But fresh research published in one of the country’s top scientific journals is helping build the case for a more cutting-edge approach that uses stem cells to restore important brain functions. The second most common neurodegenerative illness, Parkinson’s, is caused by the loss of certain nerve cells. These cells produce a chemical messenger, dopamine, that plays a crucial role regulating movement.
New research kindles excitement around stem cell therapies for Parkinson’s

4 weeks ago | yahoo.com | Jacob Bell

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The most effective drug for Parkinson’s disease hasn’t changed in 50 years. But fresh research published in one of the country’s top scientific journals is helping build the case for a more cutting-edge approach that uses stem cells to restore important brain functions.
GSK targets neurodegenerative diseases with latest licensing deal

1 month ago | biopharmadive.com | Jacob Bell

GSK is betting potentially billions of dollars that a smaller drug company’s technology can help create new treatments for brain-corroding diseases. Through a licensing deal announced Sunday, GSK has gained access to drug delivery technology from South Korea’s ABL Bio.
M&A recap: Big pharma starts the year mostly avoiding billion-dollar deals

1 month ago | biopharmadive.com | Jacob Bell

The world’s largest pharmaceutical companies mostly steered clear of billion-dollar acquisitions in the early months of this year, perhaps indicating how a tumultuous U.S. political environment has led would-be buyers to view bigger deals as too risky for the time being.